Peng

[Toni Choueiri, MD @DrChoueiri]

IO coming to breast cancer! Here with Atezolizumab in triple neg dz ⁦@US_FDA⁩ ⁦@BCRFcure⁩ ⁦@DrHBurstein⁩ ⁦@YoungStrongDFCI⁩ ⁦@elmayermd⁩ ⁦⁦@DanaFarber⁩ . Our own ⁦@DrEricWiner⁩ part of IMpassion130 trial https://t.co/4f2E8Blpti

[Carey Jansen, MD PhD @careyjans]

This is an impt distinction. Low(er) TMB =/= no immune response.

“It is crucial to understand that although a tumor’s genotype can shape its microenvironment, higher mutation rates are not necessarily equal to higher immune infiltration into the tumor.”

#ImmunoOncology

[McHeyzer-Williams @mmw_lmw]

Connecting Chronic #Inflammation to #Cancer | #NFkB as a Central Regulator: Roles in Cancer | MichaelKarin @UCSD @NatRevImmunol https://t.co/UsXqL3rLAa | #2018_Recap_Jan

[soria @jsoriamd]

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Yet another fascinating imaging study https://t.co/EcLn4l6NJg

[Stephanie L Goff, MD, FACS @slgoff_SB]

Read the stories in the link. It’s a side of my boss and colleague that many aren’t privileged to see. Happy Holidays!

[@gulleyj1 @gulleyj1]

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agen https://t.co/jfnEySPQEr via @sitcancer

[David Gandara @drgandara]

Nice review of vaccine therapies in cancer. Targeted and Immune Cancer Therapy | JAMA | JAMA Network https://t.co/GpltNoNH2p

[Dr. Darren Feldman @DrDarrenFeldman]

Our Make-an-Impact program can provide path review and tumor genomic sequencing to any patient in the world with platinum-resistant GCT. No cost and no visit to MSKCC required. Read to learn more.

[@gulleyj1 @gulleyj1]

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations https://t.co/EHhKWZM2m6

[Mate Manczinger @matemanc]

An elegant study about the selection pressure of the #immune system on #Cancer

The immune system profoundly restricts intratumor genetic heterogeneity

https://t.co/HklXOzoKmv

#tumor #immunotherapy #immunology

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Turning foes to friends: targeting cancer-associated fibroblasts - a new Review https://t.co/MOnFGUZDDm

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Great Work from Dr Gopal_Iyer and Team on epigenetic regulation of stem cell resistance to cisplatin! #precisiononcology #headandneckcancer #translationalsciencerocks https://t.co/VchSAoHlh7

[Anirban Maitra @Aiims1742]

Post-Thanksgiving food for thought on ctDNA for cancer detection.
Apparently healthy adults have circulating mutant DNA (not a surprise) but 58% are CHIP related “passenger” mutations that are also considered solid tumor “drivers”.
https://t.co/bbLSY9VNvi

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Commentary on the risk of bladder cancer (and other causes of death) after radiotherapy for prostate cancer, with @DrSpratticus and @PBlanchardMD. https://t.co/E8c22mvfTC

[d.planchard @dplanchard]

Advances 1st line IO by https://t.co/spvZxErdDB @myESMO #ESMOAsia18

[d.planchard @dplanchard]

Where we are with IO...@myESMO #esmoasia18 @peters_solange

[Jason Luke, MD, FACP, FASCO @jasonlukemd]

Cancer drug's stumbles prompt calls to rethink how #immunotherapy's are tested - Nice piece @heidiledford @nature @NatureNews w comments from @ChrisShibutani & yours truly. Need balance between rapid clinical development & scientifically rigorous data https://t.co/DttlGP3pdB

[Mason, Rice & Noble @RiceMason]

#ENASymp @EuropeanCancer: AZ drug matched to cancer mutation passes phase 2 test https://t.co/3BO6oBSZEy via @pmlivecom

[Daniel Gerlach @gerlach_d]

Richard Finn starting with a review of CDK inhibitors #enasymp